|Day's Range||28.47 - 29.29|
|52 Week Range||28.47 - 56.44|
|PE Ratio (TTM)||368.72|
|Dividend & Yield||1.36 (4.55%)|
|1y Target Est||N/A|
Teva Pharmaceuticals has experienced a rough year, but the stock could be bottoming out at current levels.
Commenting on Mylan N.V. (NASDAQ: MYL ), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. ...
Billionaires appear to have focused on drug stocks that were mired in debt in Q1.